PAREXEL announced today that the Company has acquired all of the outstanding equity securities of ATLAS Medical Services
PAREXEL International Corporation (Nasdaq: PRXL)(“PAREXEL” or the “Company”), a global clinical research organization, announced today that the Company has acquired all of the outstanding equity securities of ATLAS Medical Services (“ATLAS”), a provider of clinical research services in Turkey, the Middle East, and North Africa.
ATLAS provides services across all phases of clinical development and has therapeutic expertise in Oncology, Hematology, Endocrinology, Cardiovascular, Anesthesiology, Infectious Diseases and the Central Nervous System. The firm also provides clinical trial-related services from study planning and feasibility, through site selection, data management and medical writing. ATLAS also provides regulatory services and can support product registration.
ATLAS was founded in 2005, and works with more than 28 biopharmaceutical services companies including Top 10 major biopharmaceutical companies. The company has 35 employees and is headquartered in Istanbul, with additional offices in Ankara and Izmir. The business will be integrated into PAREXEL’s Clinical Research Services business. Prior to the sale, ATLAS was privately owned. ATLAS’s Calendar Year 2013 revenue was approximately $4 million. The acquisition was funded with existing cash, and the impact of the acquisition on PAREXEL’s Fiscal Year 2015 revenue and earnings per share is not material.
Josef von Rickenbach, Chairman and CEO of PAREXEL stated, “The acquisition of ATLAS strengthens PAREXEL’s presence in Turkey, the Middle East and North Africa. These markets are of increasing importance to our clients who are looking for market access and a broad spectrum of patient populations for clinical trials. In addition, ATLAS has been a trusted business partner to PAREXEL for many years, and their infrastructure and staff are already aligned with our processes and operations. By fully integrating ATLAS into PAREXEL’s global operations, we will enhance our ability to help clients more quickly achieve their goals of bringing important therapies to patients not only in Turkey, the Middle East, and North Africa, but also throughout the rest of the world.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.